Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Metabolomic Biomarkers in the Progression to Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. GLP-1 and Amylin in the Treatment of Obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE OF REVIEW: Hyperglucagonemia contributes significantly to hyperglycemia in type 2 diabetes and suppressed glucagon levels may increase the risk of hypoglycemia. Here, we give a brief overview of glucagon physiology and the role of glucagon in the pathophysiology of type 2 diabetes and provide insights into how antidiabetic drugs influence glucagon secretion as well as a perspective on the future of glucagon-targeting drugs.

RECENT FINDINGS: Several older as well as recent investigations have evaluated the effect of antidiabetic agents on glucagon secretion to understand how glucagon may be involved in the drugs' efficacy and safety profiles. Based on these findings, modulation of glucagon secretion seems to play a hitherto underestimated role in the efficacy and safety of several glucose-lowering drugs. Numerous drugs currently available to diabetologists are capable of altering glucagon secretion: metformin, sulfonylurea compounds, insulin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors and amylin mimetics. Their diverse effects on glucagon secretion are of importance for their individual efficacy and safety profiles. Understanding how these drugs interact with glucagon secretion may help to optimize treatment.

OriginalsprogEngelsk
TidsskriftCurrent Diabetes Reports
Vol/bind17
Udgave nummer12
Sider (fra-til)128
ISSN1534-4827
DOI
StatusUdgivet - 28 okt. 2017

ID: 51975957